Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;116(3):97-112.
doi: 10.1177/01410768231154703. Epub 2023 Feb 14.

Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study

Andrea Dennis  1 , Daniel J Cuthbertson  2 , Dan Wootton  3 , Michael Crooks  4   5 , Mark Gabbay  6 , Nicole Eichert  1 , Sofia Mouchti  1 , Michele Pansini  7 , Adriana Roca-Fernandez  1 , Helena Thomaides-Brears  1 , Matt Kelly  1 , Matthew Robson  1 , Lyth Hishmeh  8 , Emily Attree  9 , Melissa Heightman  10 , Rajarshi Banerjee  1 , Amitava Banerjee  10   11   12
Affiliations

Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study

Andrea Dennis et al. J R Soc Med. 2023 Mar.

Abstract

Objectives: To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation.

Design: Prospective cohort study.

Participants: Individuals.

Methods: In individuals recovered from acute COVID-19, we assessed symptoms, health status, and multi-organ tissue characterisation and function.

Setting: Two non-acute healthcare settings (Oxford and London). Physiological and biochemical investigations were performed at baseline on all individuals, and those with organ impairment were reassessed.

Main outcome measures: Primary outcome was prevalence of single- and multi-organ impairment at 6 and 12 months post COVID-19.

Results: A total of 536 individuals (mean age 45 years, 73% female, 89% white, 32% healthcare workers, 13% acute COVID-19 hospitalisation) completed baseline assessment (median: 6 months post COVID-19); 331 (62%) with organ impairment or incidental findings had follow-up, with reduced symptom burden from baseline (median number of symptoms 10 and 3, at 6 and 12 months, respectively). Extreme breathlessness (38% and 30%), cognitive dysfunction (48% and 38%) and poor health-related quality of life (EQ-5D-5L < 0.7; 57% and 45%) were common at 6 and 12 months, and associated with female gender, younger age and single-organ impairment. Single- and multi-organ impairment were present in 69% and 23% at baseline, persisting in 59% and 27% at follow-up, respectively.

Conclusions: Organ impairment persisted in 59% of 331 individuals followed up at 1 year post COVID-19, with implications for symptoms, quality of life and longer-term health, signalling the need for prevention and integrated care of long COVID.Trial Registration: ClinicalTrials.gov Identifier: NCT04369807.

Keywords: COVID-19; integrated care; long COVID; organ impairment; prevention; quality of life.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AD, NE, SF, MP, AR-F, HT-B, MK, MR and RB are employees of Perspectum. All other authors have no competing or conflicting interests.

Figures

Figure 1.
Figure 1.
Study population from recruitment to follow-up.
Figure 2.
Figure 2.
Proportion of individuals with long COVID and symptoms (a: at baseline in the whole cohort and in the follow-up groups; b: at baseline vs. at follow-up in the follow-up group) or impairment (c: in the whole cohort and in the follow-up groups vs. healthy controls; d: at baseline vs. at follow-up in the follow-up group). Significant differences (p < 0.05) are indicated with a star, numbers above columns indicate the sample size (n) for each group. Note for c: compared between healthy controls (grey) and at baseline for long COVID (blue).
Figure 3.
Figure 3.
Association between risk factors and: (a) severe breathlessness at baseline; (b) poor HRQoL at follow-up. Note: (a) associations predicted whole cohort symptom at baseline using baseline covariates and (b) predicted follow-up symptom using follow-up covariates in the follow-up group.
See this image and copyright information in PMC

References

    1. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al.. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4: e2128568. - PMC - PubMed
    1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102–e107. - PMC - PubMed
    1. Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol 2022; 32: e2315. - PubMed
    1. Routen A, O’Mahoney L, Ayoubkhani D, Banerjee A, Brightling C, Calvert M, et al.. Understanding and tracking the impact of long COVID in the United Kingdom. Nat Med 2022; 28: 11–15. - PubMed
    1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594: 259–264. - PubMed

Publication types

Associated data